NCT01433731 - Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions

Lymphoma, T-Cell, Cutaneous

Interventions

DRUG

placebo for SHAPE (SHP-141)

topical gelled solution

DRUG

SHAPE (SHP-141) 0.1% BID

topical gelled solution

DRUG

SHAPE (SHP-141) 0.5% BID

topical gelled solution

DRUG

SHAPE (SHP-141) 1.0% BID

topical gelled solution

Trial Locations (6)

Ohio State University, Gahanna

University Hospitals Case Medical Center, Cleveland

Cleveland Clinic, Cleveland

Northwestern University Dept of Dermatology, Chicago

MD Anderson Cancer Center, Houston

Stanford University, Stanford